Pediatric Infectious Disease

Register      Login

VOLUME 3 , ISSUE 2 ( April-June, 2021 ) > List of Articles

Antimicrobials

Remdesivir in Children

K Dhanalakshmi

Citation Information : Dhanalakshmi K. Remdesivir in Children. Pediatr Inf Dis 2021; 3 (2):74-76.

DOI: 10.5005/jp-journals-10081-1295

License: CC BY-NC 4.0

Published Online: 14-07-2021

Copyright Statement:  Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract


PDF Share
  1. Website [Internet]. [cited 2020 Oct 22]. Available from: Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis [Internet] 2020;34:101623. Available from: http://dx.doi.org/10.1016/j.tmaid.2020.101623.
  2. Website [Internet]. [cited 2020 Oct 22]. Available from: Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med [Internet] 2020;180(7):934–943. Available from: http://dx.doi.org/10.1001/jamainternmed.2020.0994.
  3. Website [Internet]. [cited 2020 Oct 22]. Available from: Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet [Internet]##thelancet.com##2020;395(10229): 1014–1015. Available from: http://dx.doi.org/10.1016/S0140-6736(20) 30633-4.
  4. Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA 2020;323(18):1824–1836. DOI: 10.1001/jama.2020.6019.
  5. Frauenfelder C, Brierley J, Whittaker E, et al. Infant with SARS-CoV-2 infection causing severe lung disease treated with remdesivir. Pediatrics [Internet] 2020;146(3):e20201701. Available from: https://pediatrics.aappublications.org/content/146/3/e20201701.abstract.
  6. Dyer O. Covid-19: remdesivir has little or no impact on survival, WHO trial shows. BMJ 2020;371:m4057. DOI: 10.1136/bmj.m4057.
  7. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181(2):271–280.e8. DOI: 10.1016/j.cell.2020.02.052.
  8. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol [Internet] 2020;92(4): 418–423. Available from: http://dx.doi.org/10.1002/jmv.26234.
  9. Fung TS, Liu DX. Coronavirus infection, ER stress, apoptosis and innate immunity. Front Microbiol 2014;5:296. DOI: 10.3389/fmicb.2014.00296.
  10. Website [Internet]. [cited 2020 Oct 22]. Available from: Gordon CJ, Tchesnokov EP, Feng JY, et al. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem [Internet] 2020;295(15):4773–4779. Available from: http://dx.doi.org/10.1074/jbc.AC120.013056.
  11. Website [Internet]. [cited 2020 Oct 22]. Available from: Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem [Internet] 2020;295(20):6785–6797. Available from: http://dx.doi.org/10.1074/jbc.RA120.013679.
  12. de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A 2020;117(12):6771–6776. DOI: 10.1073/pnas.1922083117.
  13. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30(3):269–271. DOI: 10.1038/s41422-020-0282-0.
  14. Pruijssers AJ, George AS, Schäfer A, et al. Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. bioRxiv [Internet] 2020. Available from: http://dx.doi.org/10.1101/2020.04.27.064279.
  15. Website [Internet]. [cited 2020 Oct 22]. Available from: Lamb YN. Remdesivir: first approval [internet]. Drugs 2020;80(13):1355–1363. Available from: http://dx.doi.org/10.1007/s40265-020-01378-w.
  16. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395(10236):1569–1578. DOI: 10.1016/S0140-6736(20)31022-9.
  17. Website [Internet]. [cited 2020 Oct 23]. Available from: Remdesivir for the Treatment of Covid-19 — Final Report | NEJMwww.nejm.org > doi > full > NEJMoa2007764 Oct 8.
  18. 2020 Consortium WST, WHO Solidarity Trial Consortium Pan H, Peto R, Karim QA, et al. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results [internet]. MedRxiv 2020. Available from: http://dx.doi.org/10.1101/2020.10.15.20209817.
  19. Website [Internet]. [cited 2020 Oct 23]. Available from: Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19 [internet]. N Eng J Med 2020;383(19):1827–1837. Available from: http://dx.doi.org/10.1056/nejmoa2015301.
  20. Fda US, Fact sheet for health care providers: emergency use authorization (EUA) of remdesivir (GS-5734™). 2020.
  21. Website [Internet]. [cited 2020 Oct 23]. Available from: Humeniuk R, Mathias A, Cao H, et al. Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral for treatment of COVID-19, in healthy subjects. Clin Transl Sci [Internet] 2020. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/cts.12840.
  22. Yalçın N, Demirkan K. COVID-19 and remdesivir in pediatric patients: the invisible part of the iceberg. Pediatr Res [Internet] 2020. Available from: http://dx.doi.org/10.1038/s41390-020-01109-7.
  23. Website [Internet]. [cited 2020 Oct 23]. Available from: Website [Internet]. [cited 2020 Oct 23]. Available from: Beigel JH, Tomashek KM, Dodd LE. Remdesivir for the treatment of Covid-19 - preliminary report. Reply N Engl J Med [Internet] 2020;383(10):994. Available from: http://dx.doi.org/10.1056/NEJMc2022236.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.